Recommendation of the President – flecainide

On 27 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 158/2024 on the appropriateness of authorizing the reimbursement of medicines containing the active substance flecainide in the form of prolonged-release capsules for the following indications: supraventricular arrhythmias (atrial fibrillation, atrial flutter, atrial tachycardia, atrial premature beats) and ventricular arrhythmias (ventricular premature beats, ventricular tachycardia)

Publication in Public Information Bulletin (BIP) >>